SlideShare a Scribd company logo
1 of 26
Quo vadis EU Pharmacy? The Future of Pharmacy from an EU persepctive Ivana Silva Pharmaceutical & Professional Affairs PGEU
PGEU Introduction Austria Belgium Denmark Finland France Germany Greece Ireland Italy Luxembourg Portugal Spain Sweden The Netherlands United Kingdom Bulgaria Croatia Cyprus Czech Rep Hungary Latvia Malta Norway Poland Romania Slovakia Slovenia Switzerland Turkey Members: Professional Bodies & Pharmacists’ Associations  2007: 29 countries
Mission statement  ,[object Object],[object Object],[object Object],[object Object]
Community Pharmacists  ,[object Object],[object Object],[object Object],(De)Regulation policy needs to fully take into account potential health impacts and public interest considerations
Community Pharmacists’  Added Value to the Health System ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],~ 1300 2007
From product to patient  = professional service
Community Pharmacy Services ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
The Example  of Dia betes Management
The example of high-risk  cardiac patients ,[object Object],[object Object],[object Object],[object Object],[object Object]
Community Pharmacy Services Determinants ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],STAKEHOLDER LEVEL  GOVERNMENT &  DR GROUP PROFESSIONAL LEVEL  PROFESSIONAL ASSOCIATIONS COMMUNITY PHARMACY LEVEL SERVICE PROVISION IN PHARMACY CLINICAL  ISSUES
IT use in Pharmacies   ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
2007 Into the future ,[object Object],[object Object],[object Object],[object Object]
What do EU citizens and patients expect from healthcare? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
How do EU policy-makers see healthcare? As a market As a cost As not their business As the infrastructure to ensure the universal right to health On a case by case political agenda topic
How is the pharmacist activity perceived in the EU? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object]
Future Challenges:  Resources for Health Financial Human Infrastructural Knowledge
How can the EU dimension impact the daily practice of the Pharmacy Profession? Regulatory Aspects Health Vs. Internal Market Professional Aspects
How can the EU dimension impact the daily practice of the Pharmacy Profession? ,[object Object],[object Object],[object Object],[object Object],Regulatory Aspects
How can the EU dimension impact the daily practice of the Pharmacy Profession? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Professional Aspects
How can the EU dimension impact the daily practice of the Pharmacy Profession? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Professional Aspects www.pgeu.eu
In conclusion… ,[object Object],[object Object],[object Object],[object Object],[object Object]
Into the future ,[object Object],[object Object],[object Object]
[object Object],[object Object],Hvala lijepa!
Representing European Community Pharmacists

More Related Content

What's hot

Hospital formulary
Hospital formularyHospital formulary
Hospital formularyAPOLLO JAMES
 
Drug information and poison information
Drug information and poison informationDrug information and poison information
Drug information and poison informationTHUSHARA MOHAN
 
Opportunities for Pharmacy Practice Research in Community Setting
Opportunities for Pharmacy Practice Research in Community SettingOpportunities for Pharmacy Practice Research in Community Setting
Opportunities for Pharmacy Practice Research in Community SettingPharmCare Research Group USM
 
Clinical Pharmacy Practice - Thao's presentation
Clinical Pharmacy Practice - Thao's presentationClinical Pharmacy Practice - Thao's presentation
Clinical Pharmacy Practice - Thao's presentationHA VO THI
 
GROWTH OF PHARMACOVIGILANCE IN INDIA Dr Deven V Parmar MD Vice President – Gl...
GROWTH OF PHARMACOVIGILANCE IN INDIA Dr Deven V Parmar MD Vice President – Gl...GROWTH OF PHARMACOVIGILANCE IN INDIA Dr Deven V Parmar MD Vice President – Gl...
GROWTH OF PHARMACOVIGILANCE IN INDIA Dr Deven V Parmar MD Vice President – Gl...Until ROI
 
ppt on poison information center organisation and resource
ppt on poison information center organisation and resourceppt on poison information center organisation and resource
ppt on poison information center organisation and resourceAnuragSingh799
 
The regulation of complementary medicines
The regulation of complementary medicinesThe regulation of complementary medicines
The regulation of complementary medicinesTGA Australia
 
Community pharmacy--------(Pharmaceutics)
Community pharmacy--------(Pharmaceutics)Community pharmacy--------(Pharmaceutics)
Community pharmacy--------(Pharmaceutics)Soft-Learners
 
Drug Information Center
Drug  Information CenterDrug  Information Center
Drug Information CenterHagar El Saeed
 
Rational use of medicine
Rational use of medicineRational use of medicine
Rational use of medicineMuhammad Arsal
 
Poison information center (Structural Organization and functions)
Poison information center (Structural Organization and functions)Poison information center (Structural Organization and functions)
Poison information center (Structural Organization and functions)Dr. Abhimanyu Prashar
 
Jens Heisterberg - Patient involvement in drug development and licensing
Jens Heisterberg - Patient involvement in drug development and licensingJens Heisterberg - Patient involvement in drug development and licensing
Jens Heisterberg - Patient involvement in drug development and licensingkoradk
 
Drug information center (DIC)
Drug information center (DIC)Drug information center (DIC)
Drug information center (DIC)Sameh Abdel-ghany
 
Clinical pharmacy1+1
Clinical pharmacy1+1Clinical pharmacy1+1
Clinical pharmacy1+1Mamdouh Samy
 
Drug information final
Drug information finalDrug information final
Drug information finalSitaram Khadka
 
Clinical Pharmacy
Clinical Pharmacy Clinical Pharmacy
Clinical Pharmacy MasudRana461
 

What's hot (20)

Hospital formulary
Hospital formularyHospital formulary
Hospital formulary
 
Drug information and poison information
Drug information and poison informationDrug information and poison information
Drug information and poison information
 
Opportunities for Pharmacy Practice Research in Community Setting
Opportunities for Pharmacy Practice Research in Community SettingOpportunities for Pharmacy Practice Research in Community Setting
Opportunities for Pharmacy Practice Research in Community Setting
 
Clinical Pharmacy Practice - Thao's presentation
Clinical Pharmacy Practice - Thao's presentationClinical Pharmacy Practice - Thao's presentation
Clinical Pharmacy Practice - Thao's presentation
 
GROWTH OF PHARMACOVIGILANCE IN INDIA Dr Deven V Parmar MD Vice President – Gl...
GROWTH OF PHARMACOVIGILANCE IN INDIA Dr Deven V Parmar MD Vice President – Gl...GROWTH OF PHARMACOVIGILANCE IN INDIA Dr Deven V Parmar MD Vice President – Gl...
GROWTH OF PHARMACOVIGILANCE IN INDIA Dr Deven V Parmar MD Vice President – Gl...
 
ppt on poison information center organisation and resource
ppt on poison information center organisation and resourceppt on poison information center organisation and resource
ppt on poison information center organisation and resource
 
Presenations on clinical pharmacy patient caring
Presenations on clinical pharmacy patient caringPresenations on clinical pharmacy patient caring
Presenations on clinical pharmacy patient caring
 
The regulation of complementary medicines
The regulation of complementary medicinesThe regulation of complementary medicines
The regulation of complementary medicines
 
Community pharmacy--------(Pharmaceutics)
Community pharmacy--------(Pharmaceutics)Community pharmacy--------(Pharmaceutics)
Community pharmacy--------(Pharmaceutics)
 
Hospital Pharmacy:Lecture five
Hospital Pharmacy:Lecture five Hospital Pharmacy:Lecture five
Hospital Pharmacy:Lecture five
 
Drug Information Center
Drug  Information CenterDrug  Information Center
Drug Information Center
 
Rational use of medicine
Rational use of medicineRational use of medicine
Rational use of medicine
 
Poison information center (Structural Organization and functions)
Poison information center (Structural Organization and functions)Poison information center (Structural Organization and functions)
Poison information center (Structural Organization and functions)
 
Jens Heisterberg - Patient involvement in drug development and licensing
Jens Heisterberg - Patient involvement in drug development and licensingJens Heisterberg - Patient involvement in drug development and licensing
Jens Heisterberg - Patient involvement in drug development and licensing
 
Drug information center (DIC)
Drug information center (DIC)Drug information center (DIC)
Drug information center (DIC)
 
OTC Medication
OTC MedicationOTC Medication
OTC Medication
 
Clinical pharmacy1+1
Clinical pharmacy1+1Clinical pharmacy1+1
Clinical pharmacy1+1
 
Drug information final
Drug information finalDrug information final
Drug information final
 
Clinical Pharmacy
Clinical Pharmacy Clinical Pharmacy
Clinical Pharmacy
 
Origin of healthcare funding models
Origin of healthcare funding modelsOrigin of healthcare funding models
Origin of healthcare funding models
 

Similar to Quo Vadis EU Pharmacy?

0326 150514073330-lva1-app6892
0326 150514073330-lva1-app68920326 150514073330-lva1-app6892
0326 150514073330-lva1-app6892Georgi Daskalov
 
THE ROLE OF THE PHARMACIST IN ACHIEVING THERAPEUTIC EFFICACY AND COST EFFECTI...
THE ROLE OF THE PHARMACIST IN ACHIEVING THERAPEUTIC EFFICACY AND COST EFFECTI...THE ROLE OF THE PHARMACIST IN ACHIEVING THERAPEUTIC EFFICACY AND COST EFFECTI...
THE ROLE OF THE PHARMACIST IN ACHIEVING THERAPEUTIC EFFICACY AND COST EFFECTI...Georgi Daskalov
 
Trigger Point – Self-medication: Patients in white coats
Trigger Point – Self-medication: Patients in white coats Trigger Point – Self-medication: Patients in white coats
Trigger Point – Self-medication: Patients in white coats inemet
 
European Patients' Rights Day 2015: PEDICINI (MEP)
European Patients' Rights Day 2015: PEDICINI (MEP)European Patients' Rights Day 2015: PEDICINI (MEP)
European Patients' Rights Day 2015: PEDICINI (MEP)Cittadinanzattiva onlus
 
Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?Office of Health Economics
 
WhereArePatientsinDecisionMaking
WhereArePatientsinDecisionMakingWhereArePatientsinDecisionMaking
WhereArePatientsinDecisionMakingPhilippa Göranson
 
WhereArePatientsinDecisionMaking
WhereArePatientsinDecisionMakingWhereArePatientsinDecisionMaking
WhereArePatientsinDecisionMakingSuzanne Parsons
 
Presentation for EPEMED Webinar (11-27-12) Final
Presentation for EPEMED Webinar (11-27-12) FinalPresentation for EPEMED Webinar (11-27-12) Final
Presentation for EPEMED Webinar (11-27-12) FinalStig Albinus
 
2o OTC & Cosmetics Conference, Raymond Anderson
2o OTC & Cosmetics Conference, Raymond Anderson2o OTC & Cosmetics Conference, Raymond Anderson
2o OTC & Cosmetics Conference, Raymond AndersonStarttech Ventures
 
Ilaria passarani - Selling Sickness 2010
Ilaria passarani - Selling Sickness 2010Ilaria passarani - Selling Sickness 2010
Ilaria passarani - Selling Sickness 2010Gezonde scepsis
 
Leveraging Consumer-Facing Technologies to Improve Health Outcomes
Leveraging Consumer-Facing Technologies to Improve Health OutcomesLeveraging Consumer-Facing Technologies to Improve Health Outcomes
Leveraging Consumer-Facing Technologies to Improve Health OutcomesCognizant
 
Medicines Transparency in Jordan
Medicines Transparency in JordanMedicines Transparency in Jordan
Medicines Transparency in JordanMeTApresents
 
Driving innovation procurement forward International Perspective: What can we...
Driving innovation procurement forward International Perspective: What can we...Driving innovation procurement forward International Perspective: What can we...
Driving innovation procurement forward International Perspective: What can we...Consorci de Salut i Social de Catalunya
 
Arnaud Emerieu, President of the European Social Insurance Platform, Belgium
Arnaud Emerieu, President of the European Social Insurance Platform, BelgiumArnaud Emerieu, President of the European Social Insurance Platform, Belgium
Arnaud Emerieu, President of the European Social Insurance Platform, BelgiumCittadinanzattiva onlus
 
The Pursuit of Precision Healthcare-Patient needs in personalized healthcare
The Pursuit of Precision Healthcare-Patient needs in personalized healthcareThe Pursuit of Precision Healthcare-Patient needs in personalized healthcare
The Pursuit of Precision Healthcare-Patient needs in personalized healthcareKathi Apostolidis
 
Research article Pharmacists cognitive service and pharmaceutical care today ...
Research article Pharmacists cognitive service and pharmaceutical care today ...Research article Pharmacists cognitive service and pharmaceutical care today ...
Research article Pharmacists cognitive service and pharmaceutical care today ...M. Luisetto Pharm.D.Spec. Pharmacology
 
Joint Rare Diseases / Orphan Medicinal Products Task Force
Joint Rare Diseases / Orphan Medicinal Products Task ForceJoint Rare Diseases / Orphan Medicinal Products Task Force
Joint Rare Diseases / Orphan Medicinal Products Task ForceDutch Orphan Drug Network
 

Similar to Quo Vadis EU Pharmacy? (20)

0326 150514073330-lva1-app6892
0326 150514073330-lva1-app68920326 150514073330-lva1-app6892
0326 150514073330-lva1-app6892
 
THE ROLE OF THE PHARMACIST IN ACHIEVING THERAPEUTIC EFFICACY AND COST EFFECTI...
THE ROLE OF THE PHARMACIST IN ACHIEVING THERAPEUTIC EFFICACY AND COST EFFECTI...THE ROLE OF THE PHARMACIST IN ACHIEVING THERAPEUTIC EFFICACY AND COST EFFECTI...
THE ROLE OF THE PHARMACIST IN ACHIEVING THERAPEUTIC EFFICACY AND COST EFFECTI...
 
Trigger Point – Self-medication: Patients in white coats
Trigger Point – Self-medication: Patients in white coats Trigger Point – Self-medication: Patients in white coats
Trigger Point – Self-medication: Patients in white coats
 
European Patients' Rights Day 2015: PEDICINI (MEP)
European Patients' Rights Day 2015: PEDICINI (MEP)European Patients' Rights Day 2015: PEDICINI (MEP)
European Patients' Rights Day 2015: PEDICINI (MEP)
 
ROLE OF PHARMACIST IN HEALTH CARE SYSTEM.
ROLE OF PHARMACIST IN HEALTH CARE SYSTEM.ROLE OF PHARMACIST IN HEALTH CARE SYSTEM.
ROLE OF PHARMACIST IN HEALTH CARE SYSTEM.
 
Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?Orphan Drugs – High Prices: Is there a Way Forward?
Orphan Drugs – High Prices: Is there a Way Forward?
 
WhereArePatientsinDecisionMaking
WhereArePatientsinDecisionMakingWhereArePatientsinDecisionMaking
WhereArePatientsinDecisionMaking
 
WhereArePatientsinDecisionMaking
WhereArePatientsinDecisionMakingWhereArePatientsinDecisionMaking
WhereArePatientsinDecisionMaking
 
Presentation for EPEMED Webinar (11-27-12) Final
Presentation for EPEMED Webinar (11-27-12) FinalPresentation for EPEMED Webinar (11-27-12) Final
Presentation for EPEMED Webinar (11-27-12) Final
 
2o OTC & Cosmetics Conference, Raymond Anderson
2o OTC & Cosmetics Conference, Raymond Anderson2o OTC & Cosmetics Conference, Raymond Anderson
2o OTC & Cosmetics Conference, Raymond Anderson
 
Consumer health: time for a regulatory re-think?
Consumer health: time for a regulatory re-think?Consumer health: time for a regulatory re-think?
Consumer health: time for a regulatory re-think?
 
Ilaria passarani - Selling Sickness 2010
Ilaria passarani - Selling Sickness 2010Ilaria passarani - Selling Sickness 2010
Ilaria passarani - Selling Sickness 2010
 
Leveraging Consumer-Facing Technologies to Improve Health Outcomes
Leveraging Consumer-Facing Technologies to Improve Health OutcomesLeveraging Consumer-Facing Technologies to Improve Health Outcomes
Leveraging Consumer-Facing Technologies to Improve Health Outcomes
 
Medicines Transparency in Jordan
Medicines Transparency in JordanMedicines Transparency in Jordan
Medicines Transparency in Jordan
 
Driving innovation procurement forward International Perspective: What can we...
Driving innovation procurement forward International Perspective: What can we...Driving innovation procurement forward International Perspective: What can we...
Driving innovation procurement forward International Perspective: What can we...
 
Arnaud Emerieu, President of the European Social Insurance Platform, Belgium
Arnaud Emerieu, President of the European Social Insurance Platform, BelgiumArnaud Emerieu, President of the European Social Insurance Platform, Belgium
Arnaud Emerieu, President of the European Social Insurance Platform, Belgium
 
The Pursuit of Precision Healthcare-Patient needs in personalized healthcare
The Pursuit of Precision Healthcare-Patient needs in personalized healthcareThe Pursuit of Precision Healthcare-Patient needs in personalized healthcare
The Pursuit of Precision Healthcare-Patient needs in personalized healthcare
 
Research article Pharmacists cognitive service and pharmaceutical care today ...
Research article Pharmacists cognitive service and pharmaceutical care today ...Research article Pharmacists cognitive service and pharmaceutical care today ...
Research article Pharmacists cognitive service and pharmaceutical care today ...
 
Joint Rare Diseases / Orphan Medicinal Products Task Force
Joint Rare Diseases / Orphan Medicinal Products Task ForceJoint Rare Diseases / Orphan Medicinal Products Task Force
Joint Rare Diseases / Orphan Medicinal Products Task Force
 
An introduction to the EMA
An introduction to the EMAAn introduction to the EMA
An introduction to the EMA
 

More from inemet

EUFEPS and European Initiatives in Pharmaceutical Sciences
EUFEPS and European Initiatives in Pharmaceutical SciencesEUFEPS and European Initiatives in Pharmaceutical Sciences
EUFEPS and European Initiatives in Pharmaceutical Sciencesinemet
 
Legal requirements for generics and abridged products and bioequivalence
Legal requirements for generics and abridged products and bioequivalenceLegal requirements for generics and abridged products and bioequivalence
Legal requirements for generics and abridged products and bioequivalenceinemet
 
Significance of BA/BE studies in drug research and evaluation of different as...
Significance of BA/BE studies in drug research and evaluation of different as...Significance of BA/BE studies in drug research and evaluation of different as...
Significance of BA/BE studies in drug research and evaluation of different as...inemet
 
The role of dissolution in the demonstration of bioequivalence
The role of dissolution in the demonstration of bioequivalenceThe role of dissolution in the demonstration of bioequivalence
The role of dissolution in the demonstration of bioequivalenceinemet
 
Future trends and perspectives in modern pharmaceutical biotechnology
Future trends and perspectives in modern pharmaceutical biotechnologyFuture trends and perspectives in modern pharmaceutical biotechnology
Future trends and perspectives in modern pharmaceutical biotechnologyinemet
 
Focussing on cytotoxic treatment alone is not enough
Focussing on cytotoxic treatment alone is not enoughFocussing on cytotoxic treatment alone is not enough
Focussing on cytotoxic treatment alone is not enoughinemet
 
Bioavailability and bioequivalence – problems and pitfalls
Bioavailability and bioequivalence – problems and pitfallsBioavailability and bioequivalence – problems and pitfalls
Bioavailability and bioequivalence – problems and pitfallsinemet
 
Education - Do we have a choice?
Education - Do we have a choice?Education - Do we have a choice?
Education - Do we have a choice?inemet
 
BY HELPING PEOPLE MY DREAM IS BECOMING TRUE
BY HELPING PEOPLE MY DREAM IS BECOMING TRUEBY HELPING PEOPLE MY DREAM IS BECOMING TRUE
BY HELPING PEOPLE MY DREAM IS BECOMING TRUEinemet
 
POSTGENETICS MEDICINE
POSTGENETICS MEDICINEPOSTGENETICS MEDICINE
POSTGENETICS MEDICINEinemet
 
SHARING VISION – TOWARDS BIOMEDICINE PARTNERS
SHARING VISION – TOWARDS BIOMEDICINE PARTNERSSHARING VISION – TOWARDS BIOMEDICINE PARTNERS
SHARING VISION – TOWARDS BIOMEDICINE PARTNERSinemet
 
Sightseeing Pharmacy practice - The way forward
Sightseeing Pharmacy practice - The way forwardSightseeing Pharmacy practice - The way forward
Sightseeing Pharmacy practice - The way forwardinemet
 
EU telematics in the regulation of pharmaceuticals
EU telematics in the regulation of pharmaceuticalsEU telematics in the regulation of pharmaceuticals
EU telematics in the regulation of pharmaceuticalsinemet
 
Generics and Biogenerics
Generics and BiogenericsGenerics and Biogenerics
Generics and Biogenericsinemet
 
Pharmacovigilance Workshop
Pharmacovigilance WorkshopPharmacovigilance Workshop
Pharmacovigilance Workshopinemet
 
Making knowledge matter: The Skills Inventory and the Competency Maps
Making knowledge matter: The Skills Inventory and the Competency MapsMaking knowledge matter: The Skills Inventory and the Competency Maps
Making knowledge matter: The Skills Inventory and the Competency Mapsinemet
 
Pharmacy Global Track(s)
Pharmacy Global Track(s)Pharmacy Global Track(s)
Pharmacy Global Track(s)inemet
 
EPSA Vision Of Pharmacy
EPSA Vision Of PharmacyEPSA Vision Of Pharmacy
EPSA Vision Of Pharmacyinemet
 
Final Self Medication In Croatia Du 26.5.07
Final Self Medication In Croatia Du 26.5.07Final Self Medication In Croatia Du 26.5.07
Final Self Medication In Croatia Du 26.5.07inemet
 
PharmaCon 2007 Presentation
PharmaCon 2007 PresentationPharmaCon 2007 Presentation
PharmaCon 2007 Presentationinemet
 

More from inemet (20)

EUFEPS and European Initiatives in Pharmaceutical Sciences
EUFEPS and European Initiatives in Pharmaceutical SciencesEUFEPS and European Initiatives in Pharmaceutical Sciences
EUFEPS and European Initiatives in Pharmaceutical Sciences
 
Legal requirements for generics and abridged products and bioequivalence
Legal requirements for generics and abridged products and bioequivalenceLegal requirements for generics and abridged products and bioequivalence
Legal requirements for generics and abridged products and bioequivalence
 
Significance of BA/BE studies in drug research and evaluation of different as...
Significance of BA/BE studies in drug research and evaluation of different as...Significance of BA/BE studies in drug research and evaluation of different as...
Significance of BA/BE studies in drug research and evaluation of different as...
 
The role of dissolution in the demonstration of bioequivalence
The role of dissolution in the demonstration of bioequivalenceThe role of dissolution in the demonstration of bioequivalence
The role of dissolution in the demonstration of bioequivalence
 
Future trends and perspectives in modern pharmaceutical biotechnology
Future trends and perspectives in modern pharmaceutical biotechnologyFuture trends and perspectives in modern pharmaceutical biotechnology
Future trends and perspectives in modern pharmaceutical biotechnology
 
Focussing on cytotoxic treatment alone is not enough
Focussing on cytotoxic treatment alone is not enoughFocussing on cytotoxic treatment alone is not enough
Focussing on cytotoxic treatment alone is not enough
 
Bioavailability and bioequivalence – problems and pitfalls
Bioavailability and bioequivalence – problems and pitfallsBioavailability and bioequivalence – problems and pitfalls
Bioavailability and bioequivalence – problems and pitfalls
 
Education - Do we have a choice?
Education - Do we have a choice?Education - Do we have a choice?
Education - Do we have a choice?
 
BY HELPING PEOPLE MY DREAM IS BECOMING TRUE
BY HELPING PEOPLE MY DREAM IS BECOMING TRUEBY HELPING PEOPLE MY DREAM IS BECOMING TRUE
BY HELPING PEOPLE MY DREAM IS BECOMING TRUE
 
POSTGENETICS MEDICINE
POSTGENETICS MEDICINEPOSTGENETICS MEDICINE
POSTGENETICS MEDICINE
 
SHARING VISION – TOWARDS BIOMEDICINE PARTNERS
SHARING VISION – TOWARDS BIOMEDICINE PARTNERSSHARING VISION – TOWARDS BIOMEDICINE PARTNERS
SHARING VISION – TOWARDS BIOMEDICINE PARTNERS
 
Sightseeing Pharmacy practice - The way forward
Sightseeing Pharmacy practice - The way forwardSightseeing Pharmacy practice - The way forward
Sightseeing Pharmacy practice - The way forward
 
EU telematics in the regulation of pharmaceuticals
EU telematics in the regulation of pharmaceuticalsEU telematics in the regulation of pharmaceuticals
EU telematics in the regulation of pharmaceuticals
 
Generics and Biogenerics
Generics and BiogenericsGenerics and Biogenerics
Generics and Biogenerics
 
Pharmacovigilance Workshop
Pharmacovigilance WorkshopPharmacovigilance Workshop
Pharmacovigilance Workshop
 
Making knowledge matter: The Skills Inventory and the Competency Maps
Making knowledge matter: The Skills Inventory and the Competency MapsMaking knowledge matter: The Skills Inventory and the Competency Maps
Making knowledge matter: The Skills Inventory and the Competency Maps
 
Pharmacy Global Track(s)
Pharmacy Global Track(s)Pharmacy Global Track(s)
Pharmacy Global Track(s)
 
EPSA Vision Of Pharmacy
EPSA Vision Of PharmacyEPSA Vision Of Pharmacy
EPSA Vision Of Pharmacy
 
Final Self Medication In Croatia Du 26.5.07
Final Self Medication In Croatia Du 26.5.07Final Self Medication In Croatia Du 26.5.07
Final Self Medication In Croatia Du 26.5.07
 
PharmaCon 2007 Presentation
PharmaCon 2007 PresentationPharmaCon 2007 Presentation
PharmaCon 2007 Presentation
 

Recently uploaded

epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptxMohamed Rizk Khodair
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfDivya Kanojiya
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseSreenivasa Reddy Thalla
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Badalona Serveis Assistencials
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfSasikiranMarri
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Mohamed Rizk Khodair
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptxTina Purnat
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPrerana Jadhav
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATROKanhu Charan
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfDolisha Warbi
 
maternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortalitymaternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortalityhardikdabas3
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranTara Rajendran
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxKezaiah S
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxNiranjan Chavan
 
SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptMumux Mirani
 
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfMedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfSasikiranMarri
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiGoogle
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxdrashraf369
 
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdfSGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdfHongBiThi1
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...sdateam0
 

Recently uploaded (20)

epilepsy and status epilepticus for undergraduate.pptx
epilepsy and status epilepticus  for undergraduate.pptxepilepsy and status epilepticus  for undergraduate.pptx
epilepsy and status epilepticus for undergraduate.pptx
 
Basic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdfBasic principles involved in the traditional systems of medicine PDF.pdf
Basic principles involved in the traditional systems of medicine PDF.pdf
 
Clinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies DiseaseClinical Pharmacotherapy of Scabies Disease
Clinical Pharmacotherapy of Scabies Disease
 
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
Presentació "Real-Life VR Integration for Mild Cognitive Impairment Rehabilit...
 
History and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdfHistory and Development of Pharmacovigilence.pdf
History and Development of Pharmacovigilence.pdf
 
Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)Primary headache and facial pain. (2024)
Primary headache and facial pain. (2024)
 
The next social challenge to public health: the information environment.pptx
The next social challenge to public health:  the information environment.pptxThe next social challenge to public health:  the information environment.pptx
The next social challenge to public health: the information environment.pptx
 
Presentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous SystemPresentation on Parasympathetic Nervous System
Presentation on Parasympathetic Nervous System
 
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATROApril 2024 ONCOLOGY CARTOON by  DR KANHU CHARAN PATRO
April 2024 ONCOLOGY CARTOON by DR KANHU CHARAN PATRO
 
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdfPULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
PULMONARY EMBOLISM AND ITS MANAGEMENTS.pdf
 
maternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortalitymaternal mortality and its causes and how to reduce maternal mortality
maternal mortality and its causes and how to reduce maternal mortality
 
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara RajendranMusic Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
Music Therapy's Impact in Palliative Care| IAPCON2024| Dr. Tara Rajendran
 
Tans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptxTans femoral Amputee : Prosthetics Knee Joints.pptx
Tans femoral Amputee : Prosthetics Knee Joints.pptx
 
Case Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptxCase Report Peripartum Cardiomyopathy.pptx
Case Report Peripartum Cardiomyopathy.pptx
 
SWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.pptSWD (Short wave diathermy)- Physiotherapy.ppt
SWD (Short wave diathermy)- Physiotherapy.ppt
 
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdfMedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
MedDRA-A-Comprehensive-Guide-to-Standardized-Medical-Terminology.pdf
 
Introduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali RaiIntroduction to Sports Injuries by- Dr. Anjali Rai
Introduction to Sports Injuries by- Dr. Anjali Rai
 
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptxSYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
SYNDESMOTIC INJURY- ANATOMICAL REPAIR.pptx
 
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdfSGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
SGK HÓA SINH NĂNG LƯỢNG SINH HỌC 2006.pdf
 
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...Big Data Analysis Suggests COVID  Vaccination Increases Excess Mortality Of  ...
Big Data Analysis Suggests COVID Vaccination Increases Excess Mortality Of ...
 

Quo Vadis EU Pharmacy?

  • 1. Quo vadis EU Pharmacy? The Future of Pharmacy from an EU persepctive Ivana Silva Pharmaceutical & Professional Affairs PGEU
  • 2. PGEU Introduction Austria Belgium Denmark Finland France Germany Greece Ireland Italy Luxembourg Portugal Spain Sweden The Netherlands United Kingdom Bulgaria Croatia Cyprus Czech Rep Hungary Latvia Malta Norway Poland Romania Slovakia Slovenia Switzerland Turkey Members: Professional Bodies & Pharmacists’ Associations 2007: 29 countries
  • 3.
  • 4.
  • 5.
  • 6.
  • 7. From product to patient = professional service
  • 8.
  • 9. The Example of Dia betes Management
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15. How do EU policy-makers see healthcare? As a market As a cost As not their business As the infrastructure to ensure the universal right to health On a case by case political agenda topic
  • 16.
  • 17.
  • 18. Future Challenges: Resources for Health Financial Human Infrastructural Knowledge
  • 19. How can the EU dimension impact the daily practice of the Pharmacy Profession? Regulatory Aspects Health Vs. Internal Market Professional Aspects
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.